Sanofi SA had net sales of €10.4 billion in the third quarter, up by 10% from a year earlier, and lifted by strong demand for Dupixent, the anti-inflammatory drug jointly developed with Regeneron Inc. Dupixent’s sales were €1.4 billion, or 13% of the company’s total turnover. The quarter also featured strong demand for Kevzara in rheumatoid arthritis, Libtayo in oncology, and Sarclisa in muliple myeloma.
